BACKGROUND: HER-2/neu gene amplification and protein overexpression have been identified in various solid tumors, but its prognostic relevance in head and neck squamous cell carcinoma (HNSCC) is still controversial. METHODS: The study investigated the expression of HER-2/neu oncoprotein in HNSCC and sought possible correlations to various clinicopathologic parameters. Expression of HER-2/neu oncoprotein was assessed in archival tumor tissues from 87 untreated HNSCC patients by immunohistochemical technique. Data were correlated with both the clinicopathologic parameters and patient survival. RESULTS: A high membranous HER-2/neu protein expression level was found in 39% of patients. Multivariate analysis indicated that HER-2/neu protein expression and pN lymph-node status were independent prognostic factors for disease-free survival. CONCLUSIONS: HER2/neu overexpression and its relationship with survival suggest that new therapeutic approaches targeting epidermal growth factor receptor (EGFR) family receptors could provide a new way of treating HNSCC patients with HER2/neu-positive neoplastic lesions.
BACKGROUND:HER-2/neu gene amplification and protein overexpression have been identified in various solid tumors, but its prognostic relevance in head and neck squamous cell carcinoma (HNSCC) is still controversial. METHODS: The study investigated the expression of HER-2/neu oncoprotein in HNSCC and sought possible correlations to various clinicopathologic parameters. Expression of HER-2/neu oncoprotein was assessed in archival tumor tissues from 87 untreated HNSCCpatients by immunohistochemical technique. Data were correlated with both the clinicopathologic parameters and patient survival. RESULTS: A high membranous HER-2/neu protein expression level was found in 39% of patients. Multivariate analysis indicated that HER-2/neu protein expression and pN lymph-node status were independent prognostic factors for disease-free survival. CONCLUSIONS:HER2/neu overexpression and its relationship with survival suggest that new therapeutic approaches targeting epidermal growth factor receptor (EGFR) family receptors could provide a new way of treating HNSCCpatients with HER2/neu-positive neoplastic lesions.
Authors: Vivian Wai Yan Lui; Cecilia Pik Yuk Lau; Kakiu Ho; Margaret Heung Ling Ng; Suk Hang Cheng; Sai-Wah Tsao; Chi Man Tsang; Kenny Ieng Kit Lei; Anthony Tc Chan; Tony Shu Kam Mok Journal: Invest New Drugs Date: 2010-06-23 Impact factor: 3.850
Authors: Mylin A Torres; Uma Raju; David Molkentine; Oliver Riesterer; Luka Milas; K Kian Ang Journal: Invest New Drugs Date: 2010-02-02 Impact factor: 3.850
Authors: Lori W Lee; Christopher E C Taylor; Jean-Paul Desaulniers; Manchao Zhang; Jonas W Højfeldt; Quintin Pan; Anna K Mapp Journal: Bioorg Med Chem Lett Date: 2009-09-01 Impact factor: 2.823
Authors: A C Hoover; G L Strand; P N Nowicki; M E Anderson; P D Vermeer; A J Klingelhutz; A D Bossler; J V Pottala; W J A J Hendriks; J H Lee Journal: Oncogene Date: 2009-09-07 Impact factor: 9.867